Entertainment news, movies, and celebrities
A recent study shows exercise helps maintain heart health in astronauts during long-duration space missions, vital for future Mars expeditions.
Medicaid's new tiered system for assessing medical frailty aims to streamline exemptions for the seriously ill, but raises ongoing concerns.
Novartis investors heighten scrutiny following drug trial failures and the looming expiration of key biologics patents, impacting market confidence.
Cancer treatment facilities face ongoing drug shortages, complicating patient care and raising concerns over long-term impacts on treatment efficacy.
Recent failures of cardiovascular drugs from Novartis and Novo Nordisk may hinder the industry's efforts in Lp(a) treatments.
To counteract vaccine hesitancy, the pro-vaccine movement must reignite enthusiasm and communal spirit, incorporating joy and engagement into advocacy.
The Trump administration plans to issue $500 refund checks to nearly 1 million ACA enrollees without federal subsidies, targeting key swing states prior to elections.
A recent study reveals the long-term impact of platinum-based chemotherapy on DNA mutations in children, raising concerns for future cancer risks.
The FDA has suspended Shoolin Pharma's product shipments to the U.S. due to unsanitary conditions and incomplete testing records found during an inspection.
UnitedHealth's financial support for Rep. Katherine Clark raises questions about its impact on healthcare legislation amid ongoing billing debates.
Oura reveals impressive earnings of $1.2 billion as it prepares for a public offering, positioning itself strongly in the consumer health tech space.
AstraZeneca has gained FDA approval for its latest breast cancer medication, marking a significant milestone in oncology treatment.
Novartis and Novo Nordisk encounter significant trial failures, raising concerns about their drug development strategies and future pipeline viability.
AstraZeneca's tozorakimab has significantly reduced COPD flare-ups in late-stage trials, hinting at its potential as a leading treatment option.
Inhibrx reports promising results from its OX40-targeted immunotherapy, especially in HPV-positive head and neck cancer patients, marking a notable industry breakthrough.
Roivant's experimental drug, mosliciguat, demonstrates significant efficacy in a mid-stage trial for pulmonary hypertension, signaling potential new treatment avenues.
The Phase 3 trial for Novartis' cardiovascular drug pelacarsen concluded without significant results, impacting its potential in heart disease treatment.
Key changes to Medicare Advantage plans in Boston are forcing patients, like cancer survivor Eldon Clingan, to seek new providers.
The FDA is revisiting its stance on botanical drugs as hurdles persist for clozapine use and pig kidneys emerge as a potential bridge for transplants.
The Lindsay Clancy case highlights severe issues within the U.S. healthcare system, revealing the dangers of fragmented care and lack of communication among providers.